Citizens analyst Silvan Turkcan reiterated a Market Outperform rating and $6.00 price target on Prime Medicine (NASDAQ: PRME).

The analyst commented, "PRME is focused on large in-vivo indications that can provide clear value for prime editing. We believe following the upcoming AATD arbitration (late July), the story will refocus on the technology and clinical execution with FiH data in 2027. PRME hosted a WD KOL event and highlighted the sustained need in patients that are barely served by the current SoC. Clinical-stage gene therapies are also de-risking the approach, despite the AAV-based shortcomings."

For an analyst ratings summary and ratings history on Prime Medicine click here. For more ratings news on Prime Medicine click here.

Shares of Prime Medicine closed at $3.23 yesterday.